Nov 16, 2017

A clinical trial for pediatric patients will test the safety and efficacy of enoblituzumab in solid tumors that express a specific protein, including neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, Wilms tumor, or desmoplastic small round cell tumor. Read more... 

Nov 14, 2017

B-cell lymphomas are blood cancers that affect B-cells, white blood cells that develop and mature in bone marrow in the core of most bones. Mark Roschewski, M.D., of the Lymphoid Malignancies Branch is leading a study of a new treatment for B-cell lymphomas that have not responded to radiation and chemotherapy. Read more...

Nov 9, 2017

Prostate cancer patients who have failed standard radiation therapy have the options of surgery, radioactive seed implantation or cryoablation. Deborah Citrin, M.D., of the Radiation Oncology Branch is leading a study of stereotactic body radiation therapy (SBRT) to treat prostate cancer that has recurred locally after standard radiation therapy. The goal of this study is to use a novel imaging approach to guide treatment and to define the best dose of SBRT for patients whose prostate cancer has recurred after standard radiotherapy. Read more...

Nov 7, 2017

A new phase II clinical trial to assess the safety and efficacy of a drug called selumetinib for treating patients with advanced pancreatic cancer whose tumors harbor a specific genetic marker has opened at the Center for Cancer Research and is currently recruiting participants. Read more...

Nov 3, 2017

Gray-zone lymphoma, central nervous system lymphoma and extra-nodal diffuse large B-cell lymphomas are often resistant to treatment with radiation and standard chemotherapy. Mark Roschewski, M.D., of the Lymphoid Malignancies Branch, is leading a study to determine if pembrolizumab can improve outcomes for patients with certain rare lymphomas. Read more... 

Nov 1, 2017

Non-small cell lung cancer (NSCLC) develops when abnormal lung cells begin to grow out of control. These cells can form into a tumor and spread to other areas of the body. David Schrump, M.D., of the Thoracic and Gastrointestinal Oncology Branch is leading a clinical trial of a new combination treatment for patients with advanced or metastatic NSCLC that cannot be treated surgically. Read more... 

Oct 30, 2017

When standard treatment for adult T-cell leukemia/lymphoma (ATLL) proved ineffective, Pepe Bryan and his family traveled from their home in Kingston, Jamaica, to participate in a clinical trial at the NIH Clinical Center led by Kevin Conlon, M.D., of the Lymphoid Malignancies Branch. ATLL is a rare and aggressive type of blood cancer that affects the immune system’s T cells. While receiving treatment at the Clinical Center, Pepe stayed at the Children’s Inn — a temporary residence on the NIH campus for families with children participating in clinical trials. As Pepe’s fight against cancer continues, his demeanor remains positive and hopeful. “The NIH means life to me. And The Children’s Inn is a great place. Let me tell you, it’s wonderful. They give you food and housing, and they take you on outings and activities. It’s wonderful!” Read more about Pepe's story…

Oct 27, 2017

In some types of breast cancer, the tumor cells spread more frequently to the brain. A new clinical trial run by CCR investigators will test whether a drug called temozolomide can prevent these deadly lesions from recurring. Read more... 

Sep 20, 2017

A new clinical trial tests an approach that may boost the immune system’s ability to attack tumor cells for colorectal cancer that has not responded to other therapies. Read more...

Sep 12, 2017

Currently, there is no way to accurately evaluate patients' response to treatment or to detect residual esophageal cancer without removing the esophagus. R. Taylor Ripley, M.D., of the Thoracic and Gastrointestinal Oncology Branch is leading a study to determine whether metabolomic signatures or BH3 profiling in biopsy tissues can identify patients who will likely respond well to pre-surgical treatment.  Learn more...